

## **Namuscla (mexiletine hydrochloride)**

### **Patient alert card**

*This alert card provides additional information on the risk of cardiac arrhythmia (irregular heartbeat) with Namuscla.*

*Please show it to any doctor, nurse, dentist or pharmacist if they want to treat you with other medicines (this includes medicines sold in pharmacies and herbal treatments).*

### **Why did I get this card?**

Namuscla contains mexiletine and some patients taking mexiletine may develop cardiac arrhythmia (irregular heartbeats) which can be life-threatening.

### **What should I do with this card?**

- This card should be kept with you all the time - place it for instance in your wallet or purse
- Inform your doctor/ dentist/ nurse/ pharmacist about your ongoing medications and show them this card before starting any new medication while on treatment with Namuscla

### **What are the symptoms of cardiac arrhythmia?**

Typical symptoms of cardiac arrhythmia include:

- feel like your heart is beating too hard or too fast (palpitations)
- chest pain
- shortness of breath
- light-headedness, dizziness or fainting

**Seek urgent medical attention if you experience any of these symptoms!**

## Write your treatment and doctor's details below:

Start date of taking Namuscla: \_\_\_\_\_

Patient Name: \_\_\_\_\_

Patient contact details: \_\_\_\_\_

Doctor's Name: \_\_\_\_\_

Doctor's contact number: \_\_\_\_\_

## What else do I need to know?

Your doctor should perform tests to check on your heart and electrolyte levels before and after starting mexiletine. The heart tests should include a heart wave tracing (electrocardiogram or ECG). If you have any heart problems or are at risk of developing them then you may need closer monitoring particularly after increases in the dose of mexiletine. Please follow your doctor's instructions.

**Do not take more than 3 capsules of Namuscla a day, do not take a double dose to make up for a forgotten dose.**

## Where can I get more information?

See the Namuscla package leaflet for more information or contact

EU-PV@lupin.com

or visit: [www.medicines.org.uk/emc/company/3291](http://www.medicines.org.uk/emc/company/3291)